Cargando…

Robust correlations across six SARS‐CoV‐2 serology assays detecting distinct antibody features

OBJECTIVES: As the world transitions into a new era of the COVID‐19 pandemic in which vaccines become available, there is an increasing demand for rapid reliable serological testing to identify individuals with levels of immunity considered protective by infection or vaccination. METHODS: We used 34...

Descripción completa

Detalles Bibliográficos
Autores principales: Rowntree, Louise C, Chua, Brendon Y, Nicholson, Suellen, Koutsakos, Marios, Hensen, Luca, Douros, Celia, Selva, Kevin, Mordant, Francesca L, Wong, Chinn Yi, Habel, Jennifer R, Zhang, Wuji, Jia, Xiaoxiao, Allen, Lily, Doolan, Denise L, Jackson, David C, Wheatley, Adam K, Kent, Stephen J, Amanat, Fatima, Krammer, Florian, Subbarao, Kanta, Cheng, Allen C, Chung, Amy W, Catton, Mike, Nguyen, Thi HO, van de Sandt, Carolien E, Kedzierska, Katherine
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7916820/
https://www.ncbi.nlm.nih.gov/pubmed/33680466
http://dx.doi.org/10.1002/cti2.1258
_version_ 1783657564375875584
author Rowntree, Louise C
Chua, Brendon Y
Nicholson, Suellen
Koutsakos, Marios
Hensen, Luca
Douros, Celia
Selva, Kevin
Mordant, Francesca L
Wong, Chinn Yi
Habel, Jennifer R
Zhang, Wuji
Jia, Xiaoxiao
Allen, Lily
Doolan, Denise L
Jackson, David C
Wheatley, Adam K
Kent, Stephen J
Amanat, Fatima
Krammer, Florian
Subbarao, Kanta
Cheng, Allen C
Chung, Amy W
Catton, Mike
Nguyen, Thi HO
van de Sandt, Carolien E
Kedzierska, Katherine
author_facet Rowntree, Louise C
Chua, Brendon Y
Nicholson, Suellen
Koutsakos, Marios
Hensen, Luca
Douros, Celia
Selva, Kevin
Mordant, Francesca L
Wong, Chinn Yi
Habel, Jennifer R
Zhang, Wuji
Jia, Xiaoxiao
Allen, Lily
Doolan, Denise L
Jackson, David C
Wheatley, Adam K
Kent, Stephen J
Amanat, Fatima
Krammer, Florian
Subbarao, Kanta
Cheng, Allen C
Chung, Amy W
Catton, Mike
Nguyen, Thi HO
van de Sandt, Carolien E
Kedzierska, Katherine
author_sort Rowntree, Louise C
collection PubMed
description OBJECTIVES: As the world transitions into a new era of the COVID‐19 pandemic in which vaccines become available, there is an increasing demand for rapid reliable serological testing to identify individuals with levels of immunity considered protective by infection or vaccination. METHODS: We used 34 SARS‐CoV‐2 samples to perform a rapid surrogate virus neutralisation test (sVNT), applicable to many laboratories as it circumvents the need for biosafety level‐3 containment. We correlated results from the sVNT with five additional commonly used SARS‐CoV‐2 serology techniques: the microneutralisation test (MNT), in‐house ELISAs, commercial Euroimmun‐ and Wantai‐based ELISAs (RBD, spike and nucleoprotein; IgG, IgA and IgM), antigen‐binding avidity, and high‐throughput multiplex analyses to profile isotype, subclass and Fc effector binding potential. We correlated antibody levels with antibody‐secreting cell (ASC) and circulatory T follicular helper (cTfh) cell numbers. RESULTS: Antibody data obtained with commercial ELISAs closely reflected results using in‐house ELISAs against RBD and spike. A correlation matrix across ten measured ELISA parameters revealed positive correlations for all factors. The frequency of inhibition by rapid sVNT strongly correlated with spike‐specific IgG and IgA titres detected by both commercial and in‐house ELISAs, and MNT titres. Multiplex analyses revealed strongest correlations between IgG, IgG1, FcR and C1q specific to spike and RBD. Acute cTfh‐type 1 cell numbers correlated with spike and RBD‐specific IgG antibodies measured by ELISAs and sVNT. CONCLUSION: Our comprehensive analyses provide important insights into SARS‐CoV‐2 humoral immunity across distinct serology assays and their applicability for specific research and/or diagnostic questions to assess SARS‐CoV‐2‐specific humoral responses.
format Online
Article
Text
id pubmed-7916820
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-79168202021-03-05 Robust correlations across six SARS‐CoV‐2 serology assays detecting distinct antibody features Rowntree, Louise C Chua, Brendon Y Nicholson, Suellen Koutsakos, Marios Hensen, Luca Douros, Celia Selva, Kevin Mordant, Francesca L Wong, Chinn Yi Habel, Jennifer R Zhang, Wuji Jia, Xiaoxiao Allen, Lily Doolan, Denise L Jackson, David C Wheatley, Adam K Kent, Stephen J Amanat, Fatima Krammer, Florian Subbarao, Kanta Cheng, Allen C Chung, Amy W Catton, Mike Nguyen, Thi HO van de Sandt, Carolien E Kedzierska, Katherine Clin Transl Immunology Original Article OBJECTIVES: As the world transitions into a new era of the COVID‐19 pandemic in which vaccines become available, there is an increasing demand for rapid reliable serological testing to identify individuals with levels of immunity considered protective by infection or vaccination. METHODS: We used 34 SARS‐CoV‐2 samples to perform a rapid surrogate virus neutralisation test (sVNT), applicable to many laboratories as it circumvents the need for biosafety level‐3 containment. We correlated results from the sVNT with five additional commonly used SARS‐CoV‐2 serology techniques: the microneutralisation test (MNT), in‐house ELISAs, commercial Euroimmun‐ and Wantai‐based ELISAs (RBD, spike and nucleoprotein; IgG, IgA and IgM), antigen‐binding avidity, and high‐throughput multiplex analyses to profile isotype, subclass and Fc effector binding potential. We correlated antibody levels with antibody‐secreting cell (ASC) and circulatory T follicular helper (cTfh) cell numbers. RESULTS: Antibody data obtained with commercial ELISAs closely reflected results using in‐house ELISAs against RBD and spike. A correlation matrix across ten measured ELISA parameters revealed positive correlations for all factors. The frequency of inhibition by rapid sVNT strongly correlated with spike‐specific IgG and IgA titres detected by both commercial and in‐house ELISAs, and MNT titres. Multiplex analyses revealed strongest correlations between IgG, IgG1, FcR and C1q specific to spike and RBD. Acute cTfh‐type 1 cell numbers correlated with spike and RBD‐specific IgG antibodies measured by ELISAs and sVNT. CONCLUSION: Our comprehensive analyses provide important insights into SARS‐CoV‐2 humoral immunity across distinct serology assays and their applicability for specific research and/or diagnostic questions to assess SARS‐CoV‐2‐specific humoral responses. John Wiley and Sons Inc. 2021-02-28 /pmc/articles/PMC7916820/ /pubmed/33680466 http://dx.doi.org/10.1002/cti2.1258 Text en © 2021 The Authors. Clinical & Translational Immunology published by John Wiley & Sons Australia, Ltd on behalf of Australian and New Zealand Society for Immunology, Inc. This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Original Article
Rowntree, Louise C
Chua, Brendon Y
Nicholson, Suellen
Koutsakos, Marios
Hensen, Luca
Douros, Celia
Selva, Kevin
Mordant, Francesca L
Wong, Chinn Yi
Habel, Jennifer R
Zhang, Wuji
Jia, Xiaoxiao
Allen, Lily
Doolan, Denise L
Jackson, David C
Wheatley, Adam K
Kent, Stephen J
Amanat, Fatima
Krammer, Florian
Subbarao, Kanta
Cheng, Allen C
Chung, Amy W
Catton, Mike
Nguyen, Thi HO
van de Sandt, Carolien E
Kedzierska, Katherine
Robust correlations across six SARS‐CoV‐2 serology assays detecting distinct antibody features
title Robust correlations across six SARS‐CoV‐2 serology assays detecting distinct antibody features
title_full Robust correlations across six SARS‐CoV‐2 serology assays detecting distinct antibody features
title_fullStr Robust correlations across six SARS‐CoV‐2 serology assays detecting distinct antibody features
title_full_unstemmed Robust correlations across six SARS‐CoV‐2 serology assays detecting distinct antibody features
title_short Robust correlations across six SARS‐CoV‐2 serology assays detecting distinct antibody features
title_sort robust correlations across six sars‐cov‐2 serology assays detecting distinct antibody features
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7916820/
https://www.ncbi.nlm.nih.gov/pubmed/33680466
http://dx.doi.org/10.1002/cti2.1258
work_keys_str_mv AT rowntreelouisec robustcorrelationsacrosssixsarscov2serologyassaysdetectingdistinctantibodyfeatures
AT chuabrendony robustcorrelationsacrosssixsarscov2serologyassaysdetectingdistinctantibodyfeatures
AT nicholsonsuellen robustcorrelationsacrosssixsarscov2serologyassaysdetectingdistinctantibodyfeatures
AT koutsakosmarios robustcorrelationsacrosssixsarscov2serologyassaysdetectingdistinctantibodyfeatures
AT hensenluca robustcorrelationsacrosssixsarscov2serologyassaysdetectingdistinctantibodyfeatures
AT douroscelia robustcorrelationsacrosssixsarscov2serologyassaysdetectingdistinctantibodyfeatures
AT selvakevin robustcorrelationsacrosssixsarscov2serologyassaysdetectingdistinctantibodyfeatures
AT mordantfrancescal robustcorrelationsacrosssixsarscov2serologyassaysdetectingdistinctantibodyfeatures
AT wongchinnyi robustcorrelationsacrosssixsarscov2serologyassaysdetectingdistinctantibodyfeatures
AT habeljenniferr robustcorrelationsacrosssixsarscov2serologyassaysdetectingdistinctantibodyfeatures
AT zhangwuji robustcorrelationsacrosssixsarscov2serologyassaysdetectingdistinctantibodyfeatures
AT jiaxiaoxiao robustcorrelationsacrosssixsarscov2serologyassaysdetectingdistinctantibodyfeatures
AT allenlily robustcorrelationsacrosssixsarscov2serologyassaysdetectingdistinctantibodyfeatures
AT doolandenisel robustcorrelationsacrosssixsarscov2serologyassaysdetectingdistinctantibodyfeatures
AT jacksondavidc robustcorrelationsacrosssixsarscov2serologyassaysdetectingdistinctantibodyfeatures
AT wheatleyadamk robustcorrelationsacrosssixsarscov2serologyassaysdetectingdistinctantibodyfeatures
AT kentstephenj robustcorrelationsacrosssixsarscov2serologyassaysdetectingdistinctantibodyfeatures
AT amanatfatima robustcorrelationsacrosssixsarscov2serologyassaysdetectingdistinctantibodyfeatures
AT krammerflorian robustcorrelationsacrosssixsarscov2serologyassaysdetectingdistinctantibodyfeatures
AT subbaraokanta robustcorrelationsacrosssixsarscov2serologyassaysdetectingdistinctantibodyfeatures
AT chengallenc robustcorrelationsacrosssixsarscov2serologyassaysdetectingdistinctantibodyfeatures
AT chungamyw robustcorrelationsacrosssixsarscov2serologyassaysdetectingdistinctantibodyfeatures
AT cattonmike robustcorrelationsacrosssixsarscov2serologyassaysdetectingdistinctantibodyfeatures
AT nguyenthiho robustcorrelationsacrosssixsarscov2serologyassaysdetectingdistinctantibodyfeatures
AT vandesandtcaroliene robustcorrelationsacrosssixsarscov2serologyassaysdetectingdistinctantibodyfeatures
AT kedzierskakatherine robustcorrelationsacrosssixsarscov2serologyassaysdetectingdistinctantibodyfeatures